These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25505208)

  • 21. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggressive thyroid cancer: targeted therapy with sorafenib.
    Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
    Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
    Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Wang E; Karedan T; Perez CA
    Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapies for thyroid cancer.
    Krajewska J; Jarzab B
    Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
    Gruber JJ; Colevas AD
    Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The discovery and development of sorafenib for the treatment of thyroid cancer.
    White PT; Cohen MS
    Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib makes headway on metastatic thyroid cancer.
    Cancer Discov; 2013 Jul; 3(7):OF2. PubMed ID: 23847363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
    Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    Higuchi Y; Motoki T; Ishida H; Kanamitsu K; Washio K; Oyama T; Noda T; Tsurumaru Y; Okada A; Tsukahara H; Shimada A
    BMC Cancer; 2017 Nov; 17(1):775. PubMed ID: 29162036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer.
    Haddad RI
    J Clin Oncol; 2013 Oct; 31(29):3618-20. PubMed ID: 24002516
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
    Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.